Amgen

Open: 272.81 Close: 273.75 Change: 0.94

The stock market through the eyes of an AI: Amgen Company Inc Stock.

Are looking for the most relevant information about Amgen? Investor spend a lot of time searching for information to make investment decisions in Amgen. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, share, report, present, quarter, study, year, and the most common words in the summary are: amgen, stock, market, news, report, top, company, . One of the sentences in the summary was: Board of Directors declared $2.25 per share dividend. Other searches related to this term …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Amgen announces 2024 second quarter dividend for second quarter of 2024. Board of Directors declared $2.25 per share dividend. Amgen Ohio will bring 400 full-time jobs.

Today's News

Amgen announces 2024 second quarter dividend. Board of Directors declared $2.25 per share dividend for second quarter of 2024. Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses. Sandozs biosimilars Jubbonti and Wyost approved for Amgens bone-preserving therapy denosumab. Amgen has “interpretation” issues—of the confirmatory study variety. Amgen (NASDAQ:AMGN) will report its fourth quarter and full year 2023 financial results on February 6, 2024. Amgen will lead development, manufacturing, and commercialization for KHK4083/AMG 451 for all markets globally, except Japan. Kyowa Kirin has opt-in rights to co-promote in certain other markets including Europe and Asia. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. Amgen (AMGN) reported earnings of $4.71 per share, beating the Zacks Consensus Estimate of $3.83 per share. Amgen Ohio will bring 400 full-time jobs with $40 million in annual payroll. Remote working opportunities are also available. Amgen – $148 billion Amgens total revenue in 2023, exceeded $28 billion. Eylea, used for treating eye diseases, faced competition and legal challenges but continued to perform well financially. Amgen and Sandoz are locked in ongoing litigation over Prolia and Xgeva biosimilars. Prolia sales increased 12 percent last year to more than $4 billion. Sandoz and Amgen are locked into ongoing litigation. 3 analysts just weighed in on Amgen (AMGN – Research Report ) and Cigna ( CI – Research report ) with bullish sentiments. TD Cowen maintained a Buy rating on Amgan, with a price target of $370.00. Amgen is an Equal Opportunity Employer and will consider all qualified applicants for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, protected veteran status, or disability status. Scam Advisory: Special Advisory: Please be cautious of scam recruitment offers. Amgen will present new, 52-week results from the Phase 3 SPROUT study examining the use of Otezla in children and adolescents aged 6 to 17 years with moderate to severe plaque psoriasis. Amgen also will present late-breaking findings from a Phase 3 study evaluating the efficacy and safety of Otazla. Amgen to present at the 44th annual medical conference. Peter Griffith executive vice president and chief financial officer at Amgen, and Paul Burton senior vice president, chief medical officer will present. Amgen jobs - quality assurance specialist - pqa in holly springs, north carolina, united states. Amgen (amgn) falls more steeply than broader market: what investors need to know. Amgen reported fourth-quarter 2023 adjusted earnings of $4.71 per share, which beat the Zacks Consensus Estimate of $ 4.66. Amgen closed the acquisition of Horizon Therapeutics for $27.8 billion on Oct 6, 2023.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

The game is changing. There is a new strategy to evaluate Amgen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, share, report, present, quarter, study, year, and the most common words in the summary are: amgen, stock, market, news, report, top, company, . One of the sentences in the summary was: Board of Directors declared $2.25 per share dividend. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #stock #market #news #report #top #company.